A retrospective observational database cohort study assessing the effects on renal endpoints of combining SGLT2 inhibitor and GLP-1 RA therapies compared to SGLT2 inhibitor therapy or GLP-RA monotherapies, in the routine management of type 2 diabetes
To explore the real-world effectiveness of combining sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) therapies in people with type 2 diabetes who are being treated with renin-angiotensin system (RAS) blockade medication
Manuscript for publication in scientific journal
Our study will be one of the first studies to assess the effects of SGLT2i and GLP-1RA combination therapy in the management of type 2 diabetes and its effects on kidney end points from a real-world clinical perspective
Recent trial evidence has indicated benefits on primary kidney end points for individual drugs within the SGLT2i and GLP-1RA medication class. Despite the potential benefits of combining SGLT2is and GLP-1RAs for glycemia management, there is currently limited data on kidney end points for this drug combination.
How does this research try to address the problem?
Using the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) database, we will perform a retrospective cohort study to explore the potential kidney benefits of combining SGLT2i and GLP-1RA medications. A propensity score–matched cohort of prevalent new users of SGLT2is and GLP-1RAs and those who have been prescribed SGLT2is and GLP-1RAs in combination will be identified. They will be matched based on drug histories, comorbidities, and demographics, and followed-up for up to 24 months (time window: +3 or −3 months) from time of the coprescription of an SGLT2i and GLP-1RA.
How we are planning to implement the research outputs
Findings from the study will be submitted for publication in a peer reviewed journal.
How were patients and public involved?
Patients living with diabetes and comorbidities have been involved in the design of the study. They will be further included to help with dissemination of the findings.
External project members
Project end date
Expected completion is December 2023
Partners on this project
Merck Sharp & Dohme Ltd